Program Leaders: Edward Stadtmauer, MD and Nancy Speck, PhD
The Hematologic Malignancies Program was established in 1994 to translate basic scientific discoveries into novel therapeutics for patients with myeloid and lymphoid neoplasms. The Program has two scientific aims. They are to: 1) develop a mechanisms-based understanding of the genetic, cellular, and biochemical processes regulating normal and malignant hematopoiesis, and 2) translate basic scientific discoveries into more effective and manageable therapies. Thematic areas include transcriptional, translational, and epigenetic regulation of normal and malignant hematopoietic cells; signal transduction in normal and malignant hematopoietic cells; molecular therapeutics; hematopoietic stem cell biology and transplantation; and immune-based therapies.
Hematologic Malignancies Program Membership
- Craig Bassing, PhD
- Gerd Blobel, MD, PhD
- Martin Carroll, MD
- Sara Cherry, PhD
- Adam Cohen, MD
- Kojo Elenitoba-Johnson, MD
- Robert Faryabi, PhD, MSc
- Carolyn Felix, MD
- Noelle Frey, MD, MSCE
- Alfred Garfall, MD
- Saar Gill, MD, PhD
- Elizabeth Hexner, MD, MSTR
- Stephen Liebhaber, MD
- Megan Lim, MD, PhD
- Selina Luger, MD
- Ivan Maillard, MD, PhD
- Sunita Nasta, MD, FACP
- Vikram Paralkar, MD
- David Porter, MD
- David Roth, MD, PhD
- Stephen Schuster, MD
- Nancy Speck, PhD
- Edward Stadtmauer, MD
- Jakub Svoboda, MD
- Wei Tong, PhD
- Dan Vogl, MD, MSCE
- Mariusz Wasik, MD